ERBB2 and breast carcinoma: Currently there is a randomised clinical trial underway in Europe (DETECT III trial), where women with HER2 negative advanced breast cancer bearing HER2 positive CTCs/DTCs are sorted into either a standard treatment group or a group that receives lapatinib in addition to standard care.